2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
10
Neoplasms
9
Leukemia
5
Myelodysplastic Syndromes
3
Carcinoma
3
Hematologic Diseases
2
Small Cell Lung Carcinoma
1
Sarcoma, Myeloid
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Acute Disease
1
Interventions
Cytarabine
7
Mitoxantrone
3
Cyclophosphamide
3
venetoclax
2
thymoglobulin
2
fludarabine phosphate
2
fludarabine
2
devimistat
2
Thiotepa
2
Tacrolimus
2
Rituximab
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Daunorubicin
2
Cladribine
2
vosaroxin
1
quizartinib
1
plerixafor
1
pegylated granulocyte colony-stimulating factor
1
blinatumomab
1
aldesleukin
1
Transplantation
1
Stem Cell Transplantation
1
Sorafenib
1
Sirolimus
1
Razoxane
1
Mycophenolic Acid
1
Metformin
1
Mesna
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Myeloid
×
vosaroxin
×
Clear all
NCT02658487
2025-04-15
VITAL
Vanderbilt-Ingram Cancer Center
Phase 2
Completed
42 enrolled
12 charts